Cargando…
Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer
Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase inhibitor, was approved as a third-line treatment for advanced NSCLC in China. However, predictive biomarkers ar...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354100/ https://www.ncbi.nlm.nih.gov/pubmed/32753898 http://dx.doi.org/10.2147/OTT.S257052 |
_version_ | 1783558014155882496 |
---|---|
author | Fang, Shencun Cheng, Wanwan Zhang, Meiling Yang, Rusong |
author_facet | Fang, Shencun Cheng, Wanwan Zhang, Meiling Yang, Rusong |
author_sort | Fang, Shencun |
collection | PubMed |
description | Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase inhibitor, was approved as a third-line treatment for advanced NSCLC in China. However, predictive biomarkers are currently insufficient and are urgently required. Herein, we report three pre-treated cases of advanced NSCLC with TP53 mutations, wherein these patients showed partial response to anlotinib. Moreover, the three patients have achieved a progression-free survival of 8, 6.5, and 5 months, respectively. The main toxicities were hypertension, hand-foot syndrome and fatigue. In conclusion, TP53 mutations may represent a biomarker for predicting salutary effects of anlotinib. |
format | Online Article Text |
id | pubmed-7354100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73541002020-08-03 Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer Fang, Shencun Cheng, Wanwan Zhang, Meiling Yang, Rusong Onco Targets Ther Case Series Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase inhibitor, was approved as a third-line treatment for advanced NSCLC in China. However, predictive biomarkers are currently insufficient and are urgently required. Herein, we report three pre-treated cases of advanced NSCLC with TP53 mutations, wherein these patients showed partial response to anlotinib. Moreover, the three patients have achieved a progression-free survival of 8, 6.5, and 5 months, respectively. The main toxicities were hypertension, hand-foot syndrome and fatigue. In conclusion, TP53 mutations may represent a biomarker for predicting salutary effects of anlotinib. Dove 2020-07-07 /pmc/articles/PMC7354100/ /pubmed/32753898 http://dx.doi.org/10.2147/OTT.S257052 Text en © 2020 Fang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Series Fang, Shencun Cheng, Wanwan Zhang, Meiling Yang, Rusong Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title_full | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title_fullStr | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title_short | Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer |
title_sort | association of tp53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354100/ https://www.ncbi.nlm.nih.gov/pubmed/32753898 http://dx.doi.org/10.2147/OTT.S257052 |
work_keys_str_mv | AT fangshencun associationoftp53mutationswithresponsetoanlotinibtreatmentinadvancednonsmallcelllungcancer AT chengwanwan associationoftp53mutationswithresponsetoanlotinibtreatmentinadvancednonsmallcelllungcancer AT zhangmeiling associationoftp53mutationswithresponsetoanlotinibtreatmentinadvancednonsmallcelllungcancer AT yangrusong associationoftp53mutationswithresponsetoanlotinibtreatmentinadvancednonsmallcelllungcancer |